VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now available on BioRxiv.

Plasmids have long been a key material in the manufacturing of biopharmaceuticals, especially genetic medicines such as viral and non-viral vectors used in gene and cell therapies, and mRNA vaccines for COVID-19. Conventional plasmids are built on a backbone that carries antibiotic-resistance genes to support plasmid proliferation in E. coli host cells. However, these additional genes, unrelated to the intended therapeutic functions of the plasmids, pose safety risks that raise red flags for regulatory authorities, such as the FDA, while reducing manufacturing yield and compromising therapeutic efficacy. Consequently, conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively so for some therapeutic applications.

The miniVec plasmid system utilizes a miniaturized backbone that removes antibiotic-resistance genes. The result is a plasmid system of greater clinical readiness that is safer and far cheaper to manufacture at scale, while delivering enhanced functionality across diverse applications. For researchers and therapy developers, miniVec provides a new foundation for plasmid design that aligns with the regulatory expectation of “less is more,” positioning it as a new benchmark for how plasmids will be used across the biopharmaceutical industry.

“miniVec represents a foundational shift in plasmid design,” said Dr. Bruce Lahn, Chief Scientist of VectorBuilder. “It establishes a higher baseline for safety, manufacturability, and functionality. From day one, it was designed with the clinic in mind, ensuring that therapy developers and researchers can work with a backbone that aligns with regulatory expectations while enabling budget-friendly manufacturing and superior performance.”

Built for the clinic

miniVec plasmids carry a miniaturized backbone containing a small RNA that confers constant selective pressure to maintain high plasmid copy numbers in the absence of antibiotics or any other chemical additives during fermentation. Besides avoiding the biosafety concerns and regulatory red flags associated with antibiotics, this design lightens the metabolic load on host cells, which in turn leads to much higher plasmid yield in large-scale fermentation runs. Furthermore, miniVec plasmids deliver significantly enhanced functionality in a wide range of in vitro and in vivo applications, including transient transfection, electroporation, virus packaging, transposon- and CRISPR-mediated genome integration, and naked DNA vaccination, while showing no detectable immunogenicity or toxicity. For genetic medicine developers, this translates into direct benefits: smoother GMP manufacturing, fewer regulatory hurdles, and dramatic cost savings across the development pipeline.

“miniVec is a direct response to the industry’s demand for plasmids that meet modern expectations,” said Dr. Lahn. “It is not just a major improvement, but a platform designed to advance genetic medicine by making clinical development safer, more efficient, and more cost-effective.”

“As a lab focused on gene delivery development, efficacy and safety concerns, laborious manufacturing protocols, and high-end product costs are some of our major concerns. With miniVec addressing all these key considerations, we could spend less time troubleshooting and more time focusing on the actual questions we want to answer,” said Professor Stephan Matthias at Fred Hutchinson Cancer Center.

Beyond therapeutics

Although miniVec was designed with advanced therapies in mind, its advantages extend into other applications. Plasmids without antibiotics or unnecessary additives are also valuable in food production, veterinary medicine, and synthetic biology, fields where safety and compliance are often non-negotiable.

“By stripping away unnecessary complexity, miniVec has opened new doors, from advanced therapies to food-grade applications where the same principles of safety, efficacy, and affordable manufacturing apply. We see this as a platform technology with broad relevance to how plasmids will be used across many fields in the future,” continued Dr. Lahn.

VectorBuilder’s advantage

VectorBuilder’s global CDMO infrastructure supports miniVec. By integrating plasmid design, optimization, and GMP manufacturing under one roof, VectorBuilder provides seamless handovers along each step of the genetic medicine development pipeline. This end-to-end capability underscores the company’s broader mission to accelerate drug discovery through innovative, clinically ready solutions.

About VectorBuilder

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development, and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities, and state-of-the-art GMP manufacturing facilities. With leading R&D and CDMO capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new innovative tools for life sciences research and genetic medicine.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251008507824/en/

Media Inquiries
Sarah Shkargi
sarah@tnsmediacomms.com

Logo

Tags

More Like This

SK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedside

Nobel-Potential Discovery from VectorBuilder Scientists Reveals Fundamental Mechanisms of Development

Ikarovec to Advance Pipeline With Exclusive Worldwide Option to VectorBuilder’s Intravitreal Capsid Technology

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx

VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation

Intravacc Highlights Four Integrated Vaccine Development Platforms for CDMO Partners

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

SK pharmteco Announces CGMP Qualification of its Commercial-Scale Viral Vector Manufacturing Facility in France